PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin―cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis
- Author
- UNTCH, M1 ; VON MINCKWITZ, G2 ; BECKMANN, M. W11 ; SALAT, C12 ; HARBECK, N13 ; MÜLLER, V14 ; SCHMIDT, M15 ; HASMÜLLER, S16 ; LENHARD, M16 ; NEKLJUDOVA, V2 ; LEBEAU, A17 ; LOIBL, S2 ; KONECNY, G. E3 ; FASCHING, P. A11 ; CONRAD, U4 ; FETT, W5 ; KURZEDER, C6 ; LÜCK, H.-J7 ; STICKELER, E8 ; URBACZYK, H9 ; LIEDTKE, B10
[1] Department of Obstetrics and Gynecology, Helios Klinikum Berlin-Buch, Berlin, Germany
[2] German Breast Group, Neu-Isenburg, Germany
[3] Division of Hematology and Oncology, David Geffen School of Medicine, University of California, Los Angeles, United States
[4] Department of Obstetrics and Gynecology St Barbara Hospital, Hamm, Germany
[5] Hematologic/Oncologlc Practice, Wuppertal, Germany
[6] University Women's Hospital of Ulm, Ulm, Germany
[7] Department of Obstetrics and Gynecology, Medical University of Hannover, Hannover, Germany
[8] University Women's Hospital of Freiburg, Freiburg, Germany
[9] Klinikum, Kassel, Germany
[10] Krankenhaus Bergisch, Gladbach, Germany
[11] University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany
[12] Hematologic/Oncologic Clinic München, Munich, Germany
[13] Department of Obstetrics and Gynecology, Technical University of Munich, Munich, Germany
[14] Department of Obstetrics and Gynecology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
[15] University Women's Hospital of Mainz, Mainz, Germany
[16] Department of Obstetrics and Gynecology, Ludwig-Maximilians-University Grosshadern, Munich, Germany
[17] Department of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators - Source
Annals of oncology. 2011, Vol 22, Num 9, pp 1999-2006, 8 p ; ref : 13 ref
- ISSN
- 0923-7534
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- darbepoetin alfa neoadjuvant dose-dense chemotherapy neoadjuvant dose-intensified therapy primary breast cancer
- Keyword (fr)
- Anticancéreux Cancer du sein Chimiothérapie Cyclophosphamide Darbépoétine alfa Dose forte Epirubicine Essai clinique phase III Essai clinique Etalon Etude comparative Homme Intensification Norme Paclitaxel Pronostic Préopératoire Randomisation Traitement néoadjuvant Cancer primitif Agent alkylant Anthracyclines Antimitotique Cancer Dérivé de l'oxazaphosphinane Dérivé du taxane Moutarde à l'azote Pathologie de la glande mammaire Pathologie du sein Traitement Tumeur maligne
- Keyword (en)
- Antineoplastic agent Breast cancer Chemotherapy Cyclophosphamide Darbepoetin alfa High dose Epirubicin Phase III trial Clinical trial Standard Comparative study Human Intensification Standards Paclitaxel Prognosis Preoperative Randomization Neoadjuvant treatment Primary cancer Alkylating agent Anthracyclins Antimitotic Cancer Oxazaphosphinane derivatives Taxane derivatives Nitrogen mustard Mammary gland diseases Breast disease Treatment Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del pecho Quimioterapia Ciclofosfamida Darbepoetina alfa Dosis fuerte Epirubicina Ensayo clínico fase III Ensayo clínico Marco Estudio comparativo Hombre Intensificación Norma Paclitaxel Pronóstico Preoperatorio Aleatorización Neocoadyuvante tratamiento Agente alquilante Antraciclinas Antimitótico Cáncer Oxazafosfinano derivado Taxane derivado Mostaza al nitrógeno Glándula mamaria patología Seno patología Tratamiento Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20E Mammary gland diseases / 002B20E02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24492508
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1093/annonc/mdq713 
https://dx.doi.org/10.1093/annonc/mdq713
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdq713\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:304:\"PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin\u2015cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer\u2014outcome on prognosis\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"22\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1999\";s:8:\"\u0000*\u0000epage\";s:4:\"2006\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"UNTCH\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:16:\"VON MINCKWITZ, G\";i:1;s:14:\"BECKMANN, M. W\";i:2;s:8:\"SALAT, C\";i:3;s:10:\"HARBECK, N\";i:4;s:10:\"M\u00dcLLER, V\";i:5;s:10:\"SCHMIDT, M\";i:6;s:13:\"HASM\u00dcLLER, S\";i:7;s:10:\"LENHARD, M\";i:8;s:13:\"NEKLJUDOVA, V\";i:9;s:9:\"LEBEAU, A\";i:10;s:8:\"LOIBL, S\";i:11;s:13:\"KONECNY, G. E\";i:12;s:14:\"FASCHING, P. A\";i:13;s:9:\"CONRAD, U\";i:14;s:7:\"FETT, W\";i:15;s:11:\"KURZEDER, C\";i:16;s:11:\"L\u00dcCK, H.-J\";i:17;s:12:\"STICKELER, E\";i:18;s:11:\"URBACZYK, H\";i:19;s:10:\"LIEDTKE, B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:304:\"PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin\u2015cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer\u2014outcome on prognosis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdq713\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:304:\"PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin\u2015cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer\u2014outcome on prognosis\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"22\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1999\";s:8:\"\u0000*\u0000epage\";s:4:\"2006\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"UNTCH\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:16:\"VON MINCKWITZ, G\";i:1;s:14:\"BECKMANN, M. W\";i:2;s:8:\"SALAT, C\";i:3;s:10:\"HARBECK, N\";i:4;s:10:\"M\u00dcLLER, V\";i:5;s:10:\"SCHMIDT, M\";i:6;s:13:\"HASM\u00dcLLER, S\";i:7;s:10:\"LENHARD, M\";i:8;s:13:\"NEKLJUDOVA, V\";i:9;s:9:\"LEBEAU, A\";i:10;s:8:\"LOIBL, S\";i:11;s:13:\"KONECNY, G. E\";i:12;s:14:\"FASCHING, P. A\";i:13;s:9:\"CONRAD, U\";i:14;s:7:\"FETT, W\";i:15;s:11:\"KURZEDER, C\";i:16;s:11:\"L\u00dcCK, H.-J\";i:17;s:12:\"STICKELER, E\";i:18;s:11:\"URBACZYK, H\";i:19;s:10:\"LIEDTKE, B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:304:\"PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin\u2015cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer\u2014outcome on prognosis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdq713\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdq713\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:304:\"PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin\u2015cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer\u2014outcome on prognosis\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"22\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1999\";s:8:\"\u0000*\u0000epage\";s:4:\"2006\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"UNTCH\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:16:\"VON MINCKWITZ, G\";i:1;s:14:\"BECKMANN, M. W\";i:2;s:8:\"SALAT, C\";i:3;s:10:\"HARBECK, N\";i:4;s:10:\"M\u00dcLLER, V\";i:5;s:10:\"SCHMIDT, M\";i:6;s:13:\"HASM\u00dcLLER, S\";i:7;s:10:\"LENHARD, M\";i:8;s:13:\"NEKLJUDOVA, V\";i:9;s:9:\"LEBEAU, A\";i:10;s:8:\"LOIBL, S\";i:11;s:13:\"KONECNY, G. E\";i:12;s:14:\"FASCHING, P. A\";i:13;s:9:\"CONRAD, U\";i:14;s:7:\"FETT, W\";i:15;s:11:\"KURZEDER, C\";i:16;s:11:\"L\u00dcCK, H.-J\";i:17;s:12:\"STICKELER, E\";i:18;s:11:\"URBACZYK, H\";i:19;s:10:\"LIEDTKE, B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:304:\"PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin\u2015cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer\u2014outcome on prognosis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdq713\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:304:\"PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin\u2015cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer\u2014outcome on prognosis\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"22\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1999\";s:8:\"\u0000*\u0000epage\";s:4:\"2006\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"UNTCH\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:16:\"VON MINCKWITZ, G\";i:1;s:14:\"BECKMANN, M. W\";i:2;s:8:\"SALAT, C\";i:3;s:10:\"HARBECK, N\";i:4;s:10:\"M\u00dcLLER, V\";i:5;s:10:\"SCHMIDT, M\";i:6;s:13:\"HASM\u00dcLLER, S\";i:7;s:10:\"LENHARD, M\";i:8;s:13:\"NEKLJUDOVA, V\";i:9;s:9:\"LEBEAU, A\";i:10;s:8:\"LOIBL, S\";i:11;s:13:\"KONECNY, G. E\";i:12;s:14:\"FASCHING, P. A\";i:13;s:9:\"CONRAD, U\";i:14;s:7:\"FETT, W\";i:15;s:11:\"KURZEDER, C\";i:16;s:11:\"L\u00dcCK, H.-J\";i:17;s:12:\"STICKELER, E\";i:18;s:11:\"URBACZYK, H\";i:19;s:10:\"LIEDTKE, B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:304:\"PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin\u2015cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer\u2014outcome on prognosis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:21:\"10.1093\/annonc\/mdq713\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:304:\"PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin\u2015cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer\u2014outcome on prognosis\";s:9:\"\u0000*\u0000jtitle\";s:18:\"Annals of oncology\";s:9:\"\u0000*\u0000stitle\";s:10:\"Ann. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"22\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1999\";s:8:\"\u0000*\u0000epage\";s:4:\"2006\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0923-7534\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"UNTCH\";s:10:\"\u0000*\u0000aufirst\";s:1:\"M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:20:{i:0;s:16:\"VON MINCKWITZ, G\";i:1;s:14:\"BECKMANN, M. W\";i:2;s:8:\"SALAT, C\";i:3;s:10:\"HARBECK, N\";i:4;s:10:\"M\u00dcLLER, V\";i:5;s:10:\"SCHMIDT, M\";i:6;s:13:\"HASM\u00dcLLER, S\";i:7;s:10:\"LENHARD, M\";i:8;s:13:\"NEKLJUDOVA, V\";i:9;s:9:\"LEBEAU, A\";i:10;s:8:\"LOIBL, S\";i:11;s:13:\"KONECNY, G. E\";i:12;s:14:\"FASCHING, P. A\";i:13;s:9:\"CONRAD, U\";i:14;s:7:\"FETT, W\";i:15;s:11:\"KURZEDER, C\";i:16;s:11:\"L\u00dcCK, H.-J\";i:17;s:12:\"STICKELER, E\";i:18;s:11:\"URBACZYK, H\";i:19;s:10:\"LIEDTKE, B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:304:\"PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin\u2015cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer\u2014outcome on prognosis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
